Back to Search
JAEGAK KIM, D.M.D.
D.M.D.
Oral and Maxillofacial Surgery (Dentist)
NPI: 1528592029Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Oral and Maxillofacial Surgery (Dentist)Primary
Dentist — Oral and Maxillofacial Surgery
Code: 1223S0112X
DL13281(MA)
Clinical Trials (1)
1
Linked Trials
0
Recruiting
0
With Results
Research & Publications (20)
Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab.
PMID 39978685·J Allergy Clin Immunol·2025
8-other
Proportion of CD4CD49bLAG-3Type 1 Regulatory T Cells in the Blood of Psoriasis Patients Inversely Correlates with Psoriasis Area and Severity Index.
PMID 29890167·J Invest Dermatol·2018
8-other
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
PMID 30097359·Lancet·2018
3-trial
Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment.
PMID 28927890·J Invest Dermatol·2018
3-trial
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
PMID 28423301·N Engl J Med·2017
3-trial
Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis.
PMID 27686018·Annu Rev Med·2017
6-review
The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes.
PMID 27185339·J Invest Dermatol·2016
4-observational
Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets.
PMID 26763436·J Invest Dermatol·2016
4-observational
Patients With Psoriasis and Personalized Trade-offs in Treatment Decisions-Lessons Learned From Focus Groups.
PMID 27028481·JAMA Dermatol·2016
8-other
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.
PMID 25769911·J Allergy Clin Immunol·2015
2-rct
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris.
PMID 14707118·J Exp Med·2004
4-observational
False-negative results obtained with the Gen-Probe Amplified Mycobacterium tuberculosis direct test caused by unrecognized inhibition of the amplification reaction.
PMID 19587300·J Clin Microbiol·2009
5-case
Transforming growth factor-beta (TGF-beta1) activates TAK1 via TAB1-mediated autophosphorylation, independent of TGF-beta receptor kinase activity in mesangial cells.
PMID 19556242·J Biol Chem·2009
7-preclinical
Optimal replica exchange method combined with Tsallis weight sampling.
PMID 19368436·J Chem Phys·2009
8-other
Relationship between protein folding thermodynamics and the energy landscape.
PMID 19391891·Phys Rev E Stat Nonlin Soft Matter Phys·2009
8-other
A signaling network in phenylephrine-induced benign prostatic hyperplasia.
PMID 19443575·Endocrinology·2009
7-preclinical
Linking genetically defined neurons to behavior through a broadly applicable silencing allele.
PMID 19679071·Neuron·2009
7-preclinical
HAPLOWSER: a whole-genome haplotype browser for personal genome and metagenome.
PMID 19561337·Bioinformatics·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 850 HARRISON AVE FL 6
BOSTON, MA 02118 - Phone
- (617) 414-2243
Quick Facts
- NPI
- 1528592029
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Clinical Trials
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile